The National Health Surveillance Agency (Anvisa) determined the seizure of another falsified batch of the drug Humira AC 40 mg, in the form of a pre-filled syringe. In one month, it is the second batch that has banned the use, distribution and sale of units that, according to the company Abbvie Farmacêutica, are counterfeit.
THE resolution published today determines the seizure of counterfeit units from batch 1153971 (fab. 03/2021 and valid. 02/2023).
Already the resolution published on May 4 determines the seizure of counterfeit units from batch 1146607 (fab 05/2021, val 01/2023).
In September 2021, Anvisa published resolution referring to lot 1135258 (fab. 05/2020 and valid. 04/2022)
In a note, Anvisa asks the health services that, “if they identify units with counterfeit characteristics, do not use the products and communicate the fact to the Agency, through the Health Surveillance Notification System (Notivisa)”.
In case of doubts about the origin of the product, the recommendation is to contact the Customer Service of AbbVie Farmacêutica 08000222843. Once the falsification is confirmed, the fact must be reported to Anvisa.
